Detailed Performance of Retail GLP-1 Products Deep Dive Packs Candidate 1: Tirzepatide (Mounjaro / Zepbound) Snapshot: A dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly, used for Type 2 Diabetes (Mounjaro) and obesity (Zepbound) EmarketerGrandviewresearch
Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)
Code year: FY2026 (Oct 1 2025 Sep 30 2026) Audience: Certified Coders, Auditors and Clinical Documentation Specialists Access: CCO Members Last updated: April 2026 1
Complementing healthy lifestyle habits that contribute to normal skin function
Lee SY, Chang HJ, Sung J, Kim KJ, Shin S, Cho IJ, et al
The Phase 2 trial tested doses ranging from 0.5mg to 12mg